Abstract The SARS-CoV-2 subvariant BA. 2.86 'Pirola', first identified in Denmark in August
2023, has manifested with a significantly mutated spike protein profile, suggesting a …

Effectiveness of the 50-μg mRNA-1273.214 bivalent vaccine against SARS-CoV-2 infection
was modest at 25% in a matched, retrospective, cohort study in Qatar comparing infection …

Evidence at the level of neutralizing antibodies suggests that the SARS-CoV-2 JN. 1 variant
demonstrates increased immune evasion compared to its parent lineage BA. 2.86 and to …

Objectives We assessed short-, medium-, and long-term all-cause mortality risks after a
primary SARS-CoV-2 infection. Methods A national, matched, retrospective cohort study was …

Background Bivalent mRNA vaccines were recommended since September 2022. However,
coverage with a recent vaccine dose has been limited, and there are few robust estimates of …

Cellular and humoral immunity exhibit dynamic adaptation to the mutating SARS-CoV-2
virus. It is noteworthy that immune responses differ significantly, influenced by whether a …

Objective To assess the evolution of COVID-19 severity and fatality in a unique setting that
consistently applied, throughout the pandemic, rigorous and standardised criteria for …

Background Influenza A virus have a distinctive ability to exacerbate SARS-CoV-2 infection
proven by in vitro studies. Furthermore, clinical evidence suggests that co-infection with …

Background While vaccines have established utility against COVID-19, phase 3 efficacy
studies have generally not comprehensively evaluated protection provided by previous …

Background COVID-19 epidemiology changed with the emergence of SARS-CoV-2 variants
of concern (VOC). Pakistan administered mostly inactivated vaccines. We investigated the …